KR101189865B1 - Composition comprising the salted Alaska pollack roe or Alaska pollack roe for preventing and treating obesity or hyperlipidemia and atherosclerotic-vascular diseases - Google Patents

Composition comprising the salted Alaska pollack roe or Alaska pollack roe for preventing and treating obesity or hyperlipidemia and atherosclerotic-vascular diseases Download PDF

Info

Publication number
KR101189865B1
KR101189865B1 KR1020100061802A KR20100061802A KR101189865B1 KR 101189865 B1 KR101189865 B1 KR 101189865B1 KR 1020100061802 A KR1020100061802 A KR 1020100061802A KR 20100061802 A KR20100061802 A KR 20100061802A KR 101189865 B1 KR101189865 B1 KR 101189865B1
Authority
KR
South Korea
Prior art keywords
cod roe
hyperlipidemia
cholesterol
roe
mg
Prior art date
Application number
KR1020100061802A
Other languages
Korean (ko)
Other versions
KR20120001150A (en
Inventor
권준구
김옥선
이승주
조순영
조일찬
최용석
최혜진
하왕현
Original Assignee
강릉원주대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 강릉원주대학교산학협력단 filed Critical 강릉원주대학교산학협력단
Priority to KR1020100061802A priority Critical patent/KR101189865B1/en
Publication of KR20120001150A publication Critical patent/KR20120001150A/en
Application granted granted Critical
Publication of KR101189865B1 publication Critical patent/KR101189865B1/en

Links

Abstract

The present invention relates to a composition for the prevention and treatment of obese or hyperlipidemia and arteriosclerosis vascular disease containing cod roe or cod roe as an active ingredient, in detail, the cod roe and cod roe of the present invention is liver tissue in an animal model inducing hyperlipidemia And reducing fecal lipid content, reducing serum triglycerides, cholesterol, phospholipids, lipid peroxides and Hydroxyl radicals, and enhancing SOD activity in serum. It can be used in pharmaceutical compositions and nutraceuticals useful for treatment.

Description

Composition comprising the salted Alaska pollack roe or Alaska pollack roe for preventing and treating obesity or hyperlipidemia and atherosclerotic-vascular diseases}

The present invention relates to a composition for the prevention and treatment of obese or hyperlipidemia and atherosclerotic vascular disease containing cod roe or cod roe as an active ingredient.

[Document 1] Ki-Wan Lee and 4, Evaluation of 100 Years of Korean Dietary Life (Ⅰ), Shinkwang Publishing Co., 1998

[Document 2] Kim Eun-kyung et al. 4, Life Cycle Nutrition. Shinkwang Publishing Co., 2005

[3] Seong-Hee Cho, Geology and Atherosclerosis, Korean Journal of Nutrition and Nutrition 23 (1) , pp.170-179, 1994

[Reference 4] Korea Food Industry Association Food Research Institute, A Study on the Relationship between Nutrition and Special Diseases, 1988

Illingworth, DR et al ,, Atherosclerosis, 4 , p. 270, 1984

6 Eddy, NB et al ,, Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther. 107 (3) , pp. 385-393, 1953

[7] D , Amour, FE, et al ,, A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72 , p.74, 1941

8 Imad Damaj, M. et al ,, Tolerance to the antinoceptive effect of epibatine after acute and chronic administration in mice. Euorpian J Pharmacol. 300 , pp. 51-57, 1996

[Document 9] Kim Songjeon, Kim Mansu. Effect of ω-3 Fatty Acids on Serum Lipids in Cholesterol-treated Rats, Journal of the Korean Chemical Society, 1991

[Ref 10] Effects of Fish Oil Dose on Serum Lipids in Patients with Insulin-Independent Diabetes Mellitus, Korean Journal of Nutrition, 26 (6) , pp.672-679, 1993

Schoen FJ et al., Robbins pathologic basis of disease, 5 th ed . , pp. 473-484, 1994

[Reference 12] Kook Seung-rae et al., Journal of Family Medicine, 18 (3) , pp.317-327, 1997

Reference Document 13 Ham IH et al., Kor. J, Herbology, 20 , pp. 45-52, 2005

[0014] Lee HH et al., Kor. J. Anesthesiol, 40 , pp. 515-521, 2001

15 J Choi et al., J. Kor. Pharm. Sci., 18 , pp. 240-241, 1988

16 K Kim et al., J. Kor. Pharm. Sci., 28 , pp. 15-23, 1998

Reference 17 Nash VJ et al., Pharmacotherapy, 16 , pp. 10-15, 1996

18. Stellato C. et al., Br. J. Anaesth., 67 , pp. 751-758, 1991

19 Wout GM et al., J. Paren. Sci. Technol., 46 , pp. 192-200, 1992

Rhee, S.K., et al ,, Lipid Content of Different Section and Fatty Acid Composition of Mackerel, Pacific Saury and sardine, pp. 82-88, 2001

[Ref. 21] Kim So-mi et al., Story of Korean Fish that Everyone Should Know, Hyo-il, 2002

22, Oh, S.H., Kim, D.J, .The Change in Content of Constitutive Lipid and Fatty Acid of Pacific Saury during Natural Freezing Dry (Kwa Mae Kee), Korean J. Food & Nutrition, pp.239-252, 1995

[Ref 23] Kim So-mi, Kim Eun-hee, Park Se-young, Choi Hae-hye,: Any Fish Fish Story You Should Know, Hyoil (2002)

[Reference 24] Kim Song Jeon, Kim Man Soo. Effect of ω-3 Fatty Acids on Serum Lipid Components in Cholesterol-treated Rats. Korean Journal of Petrochemicals (1991)

[Document 25] Baek Kyung, Yoon Ji Young, Yoon Seok Jung, Hyun Jung Jang, Jong Ho Lee, Eun Jik Lee, Hyun Cheol Lee, and Gabbeom Hur. Effect of Fish Oil Dose on Serum Lipids in Insulin-Independent Diabetic Patients. Korean Journal of Nutrition, 26 (6), 672-679 (1993)

[26] Yeom Dong-min, Kim Young-sook. Anticorrosive Activity of Mackerel Muscle Protein Enzyme Hydrolysates. Korean Journal of Food Science and Nutrition, Vol. 7.No. 2, 128-136 (1994)

27. Chen PS, Toribara TY, Warnerm H., Microdetermination of phosphorus, Anal . Chem 28, 1756-1760 (1956)

[28] D , Amour, FE, Smith, DLAmethodfordetermininglos

sofpainsensation.J.Pharmacol.Exp.Ther.72,74 (1941)

29 Eddy, N. B., Leimbach D. Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther. 107 (3), 385-393 (1953)

[30] Friedwald, WT, Levy, RI and Fredrickson, SD: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge, Clinical Chemistry 18, 499-502 (1972).

Illingworth, D. R. Harris, W. S and Connor, W. E: Atherosclerosis, 4, 270 (1984)

[32] Imad Damaj, M. Martin, B.R. Tolerance to the antinoceptive effect of epibatine after acute and chronic administration in mice. Euorpian J Pharmacol. 300, 51-57 (1996)

33. Kusama, H., Nishiyama, M., and Ikeda, S. Pharmacological investigation of bezafibrate a hypolipidemic agent (1). Effects of bezafibrate on normal and experimental hyperlipidemia in rats. Nippon yakurigaku Zasshi. 92, p175-180 (1988)

34. Lowry O. H., Rosebrough. N. J., Farr, A. L., and Rardall, R. J.,: J. Biol. Chem., 193, 265 (1951)

35. Mc Growan M.w. et al, Aperoxid ase-coupled method for the colorimetric determination of serum triglycerides, Clin. Chem., 29, p. 538 (1983)

36. Mirsa, H.P. and Fridovich, I., The role of superoxide aninon in the autoxidadation of epinephrine and a simple assay for superoxide dismutase. J. Biol. Chenm., 217, pp. 3170-3174 (1972)

Noma A., Matsushita S. Komori T .: High-density lipoprotein cholesterol levels of very old people in the diagnosis of dementia, Oxford Journals 15, 267-270 (1986)

38, Oh, S. H., Kim, D. J.,: The Change in Content of Constitutive Lipid and Fatty Acid of Pacific Saury during Natural Freezing Dry (Kwa MaeKee), Korean J. Food & Nutrition, 239-252 (1995)

Rhee, S.K., Cheon, S.S., Kim, D.S.,: Lipid Content of Different Section and Fatty Acid Composition of Mackerel, Pacific Saury and sardine 82-88 (2001)

40 Richmond W., Use of cholesterol oxidase for assay of total and free cholesterol in serum by continuous flow analysis, Clin. Chem., 22, 1579 (1976)

41. Winter, C.A. The search for antiinflammatory activity. Seminar in Arthritis and Rheumatism. 12 (2), 85-88 (1982)

42. Winter, C.A., Risley, E.A. and Nuss, G.W. Anti inflammatory and antipyretic actitivite of indo-methacin, 1- (p-chlorobenzoyl) -5-methoxy-2-methyl-indole-3-acetic acid. Journal of Pharmacology And Experimental Therapeutics. 141 (3), 369-376 (1963)

43 Wout G. M. et al., J. Paren. Sci. Technol., 46, pp. 192-200 (1992)

44. Yagi K., Lipid peroxides and human diseases, Chemistry and Physics of Lipids , 45, pp. 337-342 (1987)

Disease is a part of human life, and its pattern has changed with age. The economic development and high industrialization, rapid population growth and densification, environmental and health hygiene, and the development of new therapies that our society has experienced over the past 100 years have changed the disease structure of our people more than ever before. Brought. Korea's disease structure is shifting from infectious diseases to adult diseases, and the morbidity and mortality levels are changing accordingly (Kiwan et al. In terms of sign structure of Koreans, tuberculosis, bronchitis, gastroenteritis, etc. occupied the upper ranks before the 1950s. However, in 1997, the number of signs of death was circulatory disease (hypertensive disease, cerebrovascular disease, ischemic heart disease). , Arteriosclerosis, etc., accounting for 23.4% of all deaths (Eun-Kyung Kim et al. 4, Life Cycle Nutrition. Shin-Kwang Publisher, 2005). Cardiovascular disease is a major cause of premature mortality worldwide and is a multifactorial disease caused by genetics and other environmental factors. It has been reported to be closely related to lipid nutrition (Cho Sung-Hee, Lipid and Arteriosclerosis, Korea Nutrition) Korean Journal of Food Science and Technology 23 (1) , pp.170-179, 1994; Korean Food Industry Association Food Research Institute, A Study on the Relationship between Nutrition and Special Diseases, 1988).

Hyperlipidemia is the case when the concentration of serum lipids is higher than normal (Illingworth, DR et al ,, Atherosclerosis, 4 , p. 270, 1984). These symptoms are due to increased synthesis of triglycerides in the small intestine and triglycerides in the liver. Increased synthesis, decreased HDL-cholesterol synthesis, increased VDL-cholesterol synthesis and secretion (Eddy, NB et al ,, Synthetic analgesics. II.Dithienylbutenyl- and dithienylbutylamines.J Pharmacol Exp Ther. 107 (3) , pp. 385 -393, 1953; D , Amour, FE, et al ,, A method for determining loss of pain sensation.J. Pharmacol.Exp. Ther. 72 , p.74, 1941; Imad Damaj, M. et al ,, , Tolerance to the antinoceptive effect of epibatine after acute and chronic administration in mice.Europian J Pharmacol. 300 , pp.51-57, 1996) or due to tissue damage following lipid peroxidation (Kim Song-jeon, Kim Man-soo.ω-3 Effects of Fatty Acids on Serum Lipids in Cholesterol-treated Rats, Journal of the Korean Chemical Society, 1991; Non-dependent effects the amount of fish oil administered in diabetic patients on serum lipids, Korea Nutrition Society, 26 (6), pp.672-679, 1993).

In hyperlipidemia, the major components of increased serum lipid components are composed of fat-soluble substances such as cholesterol, triglycerides, phospholipids, and free fatty acids, and hypercholesterinemia, depending on which of these lipid substances increases mainly. It is called hypertriglyceridemia. Increased serum cholesterol and triglycerides are the most common causes of hyperlipidemia. Accumulation of excess fat causes blood circulation disorders and microcirculation failure, resulting in atherosclerosis, ischemic heart disease, cerebral infarction, hypertension, obesity, diabetes, etc. (Schoen FJ et al., Robbins pathologic basis of disease, 5 th ed . , pp. 473-484, 1994).

Cholesterol is produced mainly in the liver and is present in the blood in the form of small round particles called lipoproteins, which carry cholesterol throughout the body. There are two types of lipoproteins, low density lipoprotein (LDL) and high density lipoprotein (HDL), and because high density lipoproteins carry cholesterol from other tissues to the liver, a lot of high density lipoproteins remove cholesterol from blood vessels. On the other hand, low-density lipoproteins are mainly produced by the liver and transport cholesterol to other tissues of the human body, so a lot of low-density lipoproteins accumulate a lot of cholesterol in blood vessels to promote arteriosclerosis, and about 70% of blood cholesterol is present as low-density lipoproteins, which are bad cholesterol.

In fact, cholesterol is an essential ingredient for normal functioning of the human body, a nutrient necessary for making cells, and a component of various hormones such as corticosteroids, male hormones, and female hormones. do. In addition, cholesterol is a nutrient necessary for the human body such as being used as a constituent of biological membranes and as a starting material for hormonal synthesis. However, excessive cholesterol intake is known to accumulate in the blood vessels and cause heart disease, and there is no preventive method except low-cholesterol diet, and taking drugs such as cholesterol-lowering drugs is effective. Use is extremely limited due to reasons such as causing side effects such as liver dysfunction.

Chitosan, phytosterol, inositol, pectin, etc. are known to lower blood cholesterol in the human body, but the effects and metabolic mechanisms are not clear when phytosterol is excluded. not. Phytosterol, a plant sterol due to its structural similarity to cholesterol, has already been identified as a mechanism for inhibiting cholesterol absorption metabolism in the body through competition with low-density lipoprotein-cholesterol, which is harmful to the human body. As a food additive, the US Food and Drug Administration (FDA) Has been approved.

Hyperlipidemia drugs are used to lower levels of excess blood lipids, especially cholesterol and triglycerides. Major drugs used in lipid metabolism include statins, bile acid blockers and fibric acid derivatives, each of which acts as a different mechanism. The choice of therapeutic agents for hyperlipidemia may be a combination of these drugs, depending on the type of lipoproteins that have been increased, and they require long-term oral daily use. These drugs effectively lower cholesterol and blood lipid levels, but have the disadvantage of having side effects. Statins can cause nausea, headache, abdominal pain and diarrhea or constipation, which can cause muscle inflammation, and bile acid blockers can reduce the intestinal absorption of vitamins A, D, and K. And fibric acid derivatives are unsuitable drugs for kidney disease, liver disease or gallbladder disease. Therefore, there is an increasing demand for the development of medicines and functional foods containing natural products to replace these preparations (Kook Seung-rae et al., 18 (3) , pp.317-327, 1997).

Atherosclerosis causes vascular diseases such as stroke and coronary artery disease. In particular, angina and acute myocardial infarction caused by coronary artery disease have increased significantly over the last 20-30 years due to rapid social and economic development and westernized lifestyle. Arteriosclerosis is the second most common circulatory disease after hypertension, and it is one of the most important diseases in national health, with cancer accounting for a large portion of deaths. Therefore, the importance of research on the pathogenesis and treatment of atherosclerosis is increasing.

There are many causes of atherosclerosis, but elevated plasma lipids, particularly plasma cholesterol and neutral lipids, are known as one of the most important risk factors.

Hyperlipidemia is an important risk factor for atherosclerosis and is a clinically important condition that causes major deaths such as ischemic heart disease and cerebrovascular disorders. Atherosclerosis prevention is known to be associated with improved lipid and hyperlipidemia.

The pathological model of experimental hyperlipidemia is divided into exogenous model and endogenous model. Exogenous hyperlipidemic condition models include hypercholesterolemia-induced models caused by high cholesterol dietary load, that is, hyperlipidemia by administration of vitamin D, cholesterol, olive oil, corn oil, etc., and endogenous hyperlipidemia models include fructose administration and WR. Models by administration of -1339 (Tripton WR-1339) (Ham IH et al., Kor. J, Herbology, 20 , pp. 45-52, 2005). Among them, Poloxamer 407 is an anesthetic emulsifier (Lee HH et al., Kor. J. Anesthesiol, 40 , pp. 515-521, 2001), poorly soluble drug solubilizer (Choi JY et al., J. Kor. Pharm. Sci., 18 , pp. 240-241, 1988), skin ointments (Kim KK et al., J. Kor. Pharm. Sci., 28 , pp. 15-23, 1998), and the like. However, when administered in humans, lipids are increased, and in particular, triglycerides are increased, causing hyperlipidemia. Free fatty acids are produced in adipocytes for at least 24 hours after poloxamer injection (Nash VJ et al., Pharmacotherapy, 16 , pp. 10-15, 1996), and the action of lipoprotein lipase (LPL) Decreases the rate of degradation of triglycerides that interfere with it (Stellato C. et al., Br. J. Anaesth., 67 , pp.751-758, 1991), and increases blood cholesterol and triglycerides in the liver. This is because it lowers the activity of hydroxy-3-methylglutaryl coenzyme A (HMG-CoA; 3-hydroxy-3-methylglutaryl CoA) (Wout GM et al., J. Paren. Sci. Technol., 46 , pp. 192-200, 1992).

Lipid peroxidation in the blood is known to cause cytotoxicity and cause aging and pathologies of various diseases and detoxification by the action of detoxification mechanisms (Rhee, SK, et al ,,, Lipid Content of Different Section and Fatty Acid Composition of Mackerel, Pacific Saury and sardine, pp. 82-88, 2001; Kim So Mi et al., Hyo Il, 2002; Oh, SH, Kim, DJ, .The Change in Content of Constitutive Lipid and Fatty Acid of Pacific Saury during Natural Freezing Dry (Kwa Mae Kee), Korean J. Food & Nutrition, pp.239-252, 1995).

Fermented foods have been widely used in Korea, Japan and Southeast Asia, where rice is a staple food. The origin of the literature on salted salted saltfish in Korea was the first record of Samguk Sagi, which was contained in the waste white goods when the queen was greeted by King Shilla three years (683). Salted seafood was used in the manufacturing process, and since then, it has been changed in various forms as it is divided into salted sea salt (now salted salted fish) and salt, malt, and cooked grains (fish snails). .

Salted seafood is a traditional Korean fermented food product that suppresses the growth of decayed bacteria by salting fish and shellfish and decomposes meat by the action of autodigestive enzymes or microorganisms.The manufacturing process is simple and no special manufacturing equipment is required. The products after maturation have a unique umami, and they have been widely used as seasonings for side dishes or kimchi from ancient times to today. However, since salted salt is traditionally used in high concentrations of salt, it has been avoided by consumers since it is found that the main ingredient of salt is one of the causes of adult diseases, and it is urgently needed for products of salted salted salted salt.

Salted anchovy, shrimp, canary, and anchovy salted salts from other regions are at least 20% high-fat foods, while seasoned salted fish such as cod roe, flatfish, cod roe, squid marinated fish, and languid fish are made from Sokcho. It shows a very low salt concentration of ~ 4.9%, and without the concern of adult diseases such as high blood pressure caused by salt, rather, a large amount of functional free amino acids, GABA, conjugated fatty acids produced during fermentation are produced and added to the functionality of the seafood itself. This is expected to be further enhanced.

Therefore, the present inventors have continuously studied the effects of obese or hyperlipidemia and the prevention and treatment of arteriosclerosis cardiovascular disease by cod roe and colic, and resulted in the neutralization of blood in an animal model inducing hyperlipidemia by administration of Poloxamer-407 or Triton WR-1339. It has been shown to reduce fat and cholesterol content, and to reduce lipid content in liver tissue and feces in animal models that induced hyperlipidemia by high cholesterol diet, and to reduce triglyceride, cholesterol, phospholipid, peroxide and hydroxyl radical content in serum. It was confirmed that it reduces and enhances the SOD activity in the serum, and confirmed that it contains a large amount of conjugated fatty acid, which is known to be excellent in anti-obesity, anti-cancer, and antioxidant effects.

In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention and treatment of obesity or hyperlipidemia and atherosclerotic vascular disease containing cod roe or cod roe as an active ingredient.

In addition, the present invention provides a dietary supplement for the prevention and improvement of obesity or hyperlipidemia and atherosclerotic vascular disease containing cod roe or cod roe as an active ingredient.

Cod roe and cod roe as defined herein include in the form of a commonly distributed product or a dry powder thereof, preferably in the form of a dry powder.

Hyperlipidemia and atherosclerotic vascular diseases as defined herein are specifically hyperlipidemia, arteriosclerosis, heart failure, hypertensive heart disease, arrhythmia, congenital heart disease, myocardial infarction, angina pectoris, stroke or peripheral vascular disease, preferably hyperlipidemia or arteriosclerosis to be.

Hereinafter, the method of obtaining the cod roe and cod roe powder of the present invention will be described in detail.

For example, a first step of collecting and washing washed cod roe and immersed cod roe in the seasoning solution for 1 hour to 60 hours, preferably 10 hours to 50 hours; Red pepper powder, sugar, garlic, starch syrup, etc., are added to the seasoned cod roe to ripen at 0 ° C. to 50 ° C., preferably 5 ° C. to 45 ° C. for 1 hour to 60 hours, preferably 10 hours to 50 hours. Preparing a second step; The dried cod roe and cod roe powder of the present invention may be obtained through the third step of manufacturing the freeze dried cod roe and powder.

In the first step, the seasoning liquid used in the present invention has a relative compounding weight ratio (w / w) of 11.4% salt, 4.5% seasoning powder, 2% sorbitol, and 2% alcohol 5 to 20: 3 to 10: 1 to 3 : 1 to 3, preferably 5 to 15: 3 to 8: 1 to 3: 1 to 3, characterized in that the composition is mixed with seasoning liquid.

In the second step, the relative weight ratio (w / w) of the red pepper powder, sugar, garlic, syrup, etc., preferably pepper powder, sugar, garlic syrup, etc., in the seasoned cod roe is 3-15: 1-10: 1: 1. 1-3, preferably 7-10: 2-5: 1: 1-2, 1-2, more preferably 7-9: 2-4: 1-1.5: 1-1.5. It is characterized by blending the additional components of the composition.

Accordingly, the present invention provides a pharmaceutical composition for the prevention and treatment of obesity or hyperlipidemia and atherosclerotic vascular disease, comprising cod roe or cod roe obtained by the above production method as an active ingredient.

The pharmaceutical composition of the present invention comprises 0.1 to 50% by weight of the cod roe and cod roe relative to the total weight of the composition.

However, the composition is not limited thereto, and may vary depending on the condition of the patient, the type of disease, and the progress of the disease.

Cod roe and cod roe itself of the present invention is a drug that can be used with confidence even when taken for a long time for the purpose of prevention because there is little toxicity and side effects.

The compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.

The composition of the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions, Examples of carriers, excipients and diluents that can be included in the composition containing the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The preferred dosage of the composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the cod roe and cod roe of the present invention may be administered at 0.5 g / kg to 5 g / kg, preferably at 1 g / kg to 3 g / kg. The administration may be carried out once a day or divided into several doses. Thus, the dosage amounts are not intended to limit the scope of the invention in any manner.

The composition of the present invention may be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.

In another aspect, the present invention provides a dietary supplement for the prevention and improvement of obesity or hyperlipidemia and atherosclerotic vascular disease disease containing cod roe or cod roe obtained by the above method as an active ingredient.

The composition including the cod roe and cod roe of the present invention may be used in a variety of drugs, foods and beverages for the prevention and improvement of obesity or hyperlipidemia and atherosclerotic vascular disease. The food which can be added to the cod roe and cod roe of the present invention includes, for example, various foods, beverages, gums, teas, vitamin complexes, health supplements, and the like, and are in the form of powders, granules, tablets, capsules, or beverages. Can be used.

Cod roe and cod roe of the present invention may be added to food or beverage for the purpose of preventing and improving obesity or hyperlipidemia and atherosclerotic vascular disease. At this time, the amount of the cod roe and cod roe in the food or beverage is generally added to the health food composition of the present invention 1 to 5% by weight of the total food weight, the health beverage composition is 0.02 to 10 g based on 100 ml, Preferably it can be added in the ratio of 0.3-1 g.

The health beverage composition of the present invention contains the above-mentioned cod roe and cod roe as essential ingredients in the indicated ratio, and there are no special limitations in the liquid component, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. have. Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like Sugar, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 mL of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and vegetable beverages. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

Cod roe and cod roe reduce the lipid content of liver tissue and feces in the hyperlipidemia-induced animal model, decrease triglyceride, cholesterol, phospholipid, lipid peroxide and Hydroxyl radical content in serum, and enhance SOD activity in serum. It has been confirmed that it contains a large amount of conjugated fatty acid, which is known to be excellent in anti-obesity, anti-cancer, and antioxidant effects. It is used in pharmaceutical compositions and health functional foods useful for the prevention and treatment of obesity or hyperlipidemia and atherosclerotic vascular disease Can be.

Hereinafter, the present invention will be described in detail by reference examples, examples and experimental examples.

However, the following Reference Examples, Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Reference Examples, Examples and Experimental Examples.

Example  1. Preparation of cod roe and cod lyophilisate

Pollack from pollock caught in Sokcho was harvested, washed, sorted, and selected. Cod was seasoned with 11.4% salt, 4.5% seasoning powder, 2% sorbitol, 2% alcohol and 2% alcohol. (1 to 10%), sugar (1 to 10%), garlic (1 to 10%), starch syrup (1 to 10%), and the like were added and matured at 0-10 ° C. for 48 hours at low temperature to prepare cod roe.

The dried cod roe and cod roe were freeze-dried with a freeze-drier (PVTFD 300R-Korea Ilshin Lab) to obtain cod roe powder (hereinafter referred to as "MR-D") and cod roe powder (hereinafter referred to as "MR"). Was used as a sample.

Reference Example  1. Preparation for Experiment

1-1. Experimental Animal, Experimental  Configuration

Four weeks old males were obtained from SPF 25 ± 3 g ICR male mice and 140 ± 10 g Sprague Dawley (SD) rats (Hyochang Science Co., Ltd.). After healthy breeding, only healthy animals were used for the experiment. The breeding environment of the test was set at 22 ± 3 ℃, 50 ± 10% relative humidity, and 12 hours of illumination time (07: 00-19: 00). ). Feed was freely ingested for drinking water, which was a solid feed for animals (Central Experimental Animal, Seoul). 24 hours before the experiment time only watering and fasting. At this time, the experimental animals were treated within a predetermined time (10: 00-12: 00 am) in consideration of the daily variation of enzyme activity.

1-2. Sample  Produce

Samples were administered using 100% and 200 mg / kg doses of oral needle zonde for 4 weeks using 4% tween 80 diluted with coarse powder and cod roe powder.

1-3. Statistical analysis

The mean ± standard deviation of the results of three experiments was shown. To test the homogeneity of variance, Duncan's multiple range test was performed to determine statistical significance when the difference was less than 5% ( p <0.05). (Meaning that there is a statistically significant difference between the superscript alphabets in the data).

Experimental Example  1. Hyperlipidemia and lipid content measurement experiment

1-1. Poloxamer Hyperlipidemia with -407 administration

According to the method of Wout (Wout GM et al., 1992), poloxamer-407 (300mg / kg) was dissolved in physiological saline in an ice bath on the last day of administration of the sample, and the mice were intraperitoneally administered and killed 24 hours later.

1-2. Triton WR - By 1339  Hyperlipidemia

According to the method of Kusama (Kusama, H et al., 1988), fasting for 16 hours prior to Triton WR-1339 administration, and then triton WR-1339 200mg / kg injected into the tail vein to induce hyperlipidemia and CO after 18 hours 2 Blood was collected by anesthesia with gas.

1-3. Cholesterl  Induction of induced hyperlipidemia

The induction of dietary cholesterol hyperlipidemia in experimental animals was induced by breeding a preparation sample containing sodium cholate and cholesterol for 6 weeks (see Table 1).

Figure 112010041851958-pat00001

1-4. Serum and Enzyme  pharmacy

After the sample was injected, the animal was lightly anesthetized with CO 2 , and blood was collected from the abdominal aorta. The collected blood was left for 30 minutes and centrifuged at 3,000 rpm for 10 minutes to separate serum and lipid, lipid peroxide, hydroxyl radical. The content and superoxide dismutase activity were measured.

1-5. Body weight and fat tissue weight measurement

Body weight change was measured every week from the start of the experiment, the weight of the adipose tissue was calculated by taking the fat around the abdominal cavity and testicles.

1-6. Liver tissue  And Feces  Heavy lipid content measurement

Liver tissues were weighed and stored frozen at -70 o C, and feces were collected for the last 4 days. Triglycerides and cholesterol were measured by Folch et al. In other words, the stools were lyophilized and ground to be powdered. The liver tissues were cut and then ground with a teflon homogenizer. 10 times the amount of solvent (chloroform: methanol = 2: 1) was added to the sample, and the lipids were repeatedly extracted. The filtrate was put in a water container and concentrated under reduced pressure to obtain lipids. Methanol was added thereto to dissolve well, and then quantified using kit (Asan Pharmaceuticals) using the enzyme method.

1-7. Total cholesterol  Content measurement

Experiments were carried out using a kit (AM 202-K, Asan) prepared by the enzyme method of Richmond (Richmond W et al., 1976).

Enzyme reagents (containing 20.5 U / l cholesterol, oxidase 10.7 U / l, and sodium hydroxide 1.81 g / l) were dissolved in enzyme reagent solution (potassium phosphate monobasic 13.6 g / l, phenol 1.88 g / l). 3.0 ml of the enzyme solution prepared in 20 µl of the sample was added to the dissolved solution, followed by incubation at 37 ° C. for 5 minutes, and the absorbance was measured at a wavelength of 500 nm using the reagent blank as a control. The blood content was expressed in mg / dl according to the standard calibration curve.

1-8. Triglyceride  Content measurement

Experiments were performed using a kit (AM 157S-K, Asan) prepared according to the method of McGowan (McGrowan Mw et al., 1983). Enzyme reagents (containing lipoprotein lipase 10800U, glycerol kinase 5.4U, peroxidase 135000U, and L-α-glycero phosphooxidase 160U) in ice-cold phase were dissolved in enzyme reagent [N, N-bis (2-hydroxyethyl) -2-aminomethane sulfonic acid 0.427 g / dl], 3.0 ml of the enzyme solution prepared in 20 µl of the sample was added to the solution, and incubated at 37 ° C for 10 minutes, and the absorbance was measured at a wavelength of 500 nm using the reagent blank as a control. The blood content was expressed in mg / dl according to the standard calibration curve.

1-9. Phospholipid  Content measurement

Experiments were carried out using a kit (Iatron Chem. Co.) prepared by the enzyme method of Chen (Chen PS et al., 1956). In an ice-cooled solution, the enzyme reagent (containing phospholipase 3.9U, choline oxidase 5.6U, peroxidase 3.6U, and 4-aminoantipyrine 0.3252 mg) was dissolved in enzyme reagent solution [containing tris (hydroxymethyl) -aminomethane 6.057 mg]. 3.0 ml of the prepared enzyme solution was added, followed by incubation at 37 ° C. for 20 minutes to measure absorbance at a wavelength of 500 nm. The content was expressed in mg / dl according to the standard calibration curve.

1-10. High density lipoprotein - cholesterol ( HDL -C) content determination

The experiment was carried out using a kit (AM 203-K, Asan) prepared by the enzyme method of Noma (Noma A et al., 1986). 0.2 ml of sedimentation reagent (containing dextran sulfate 0.1% and magnesium chloride 0.1M) was added to 20 µl of serum, and the mixture was mixed well, left at room temperature for 10 minutes, and centrifuged at 3000 rpm for 10 minutes. 0.1 ml of the supernatant was mixed well with 3.0 ml of enzyme solution, incubated at 37 ° C. for 5 minutes, and the absorbance was measured at a wavelength of 500 nm using the reagent blank as a control. The content was expressed in mg / dl according to the standard calibration curve.

1-11. LDL -And VLDL - chlesterol  Content measurement

Low density lipoprotein-cholesterol (LDL-C) content was calculated by Equation 1 according to the method of Fridewald (Friedwald, W. T et al., 1972).

Figure 112010041851958-pat00002

The measurement of VLDL (Very low density lipoprotein) content was calculated by the formula of serum total cholesterol-(HDL-C + LDL-C). Atherosclerotic index (AI) was calculated by the formula (serum cholesterol-HDL-C) / HDL-C.

1-12. Blood Lipid peroxide  Content measurement

According to the method of Yagi (Yagi K. 1987), add 4.0 ml of 1 / 12N H 2 SO 4 to 20 µl of serum, mix 0.5 ml of 10% phosphotungstic acid, and leave it at room temperature for 5 minutes, and then centrifuge to remove the serum. The protein was taken out and centrifuged again with 2.0 ml of 1 / 12N H 2 SO 4 and 0.3 ml of 10% phosphotungstic acid. 1.0 ml of a solution of 4.0 ml of distilled water, a mixture of 0.67% thiobarbituric acid and acetic acid in a 1: 1 manner was added thereto, and the mixture was reacted at 95 ° C. for 60 minutes, cooled at room temperature, and 5.0 ml of n-BuOH was added. After centrifugation for a minute, the resulting red n-BuOH was taken and the absorbance was measured using a spectrofluorometer (Ex: 515 nm, Em: 553 nm). Tetraethoxypropane 0.5 nmole was reacted with the standard solution in the same manner to measure absorbance, and the serum lipid peroxide content was calculated by the following Equation 2.

Figure 112010041851958-pat00003

1-13. Blood Hydroxyl radical  Content measurement

According to the method of Kobatake (Kobatake Y et al., 1987), in 34.8 μl of serum, 333.3 μl of 0.54 M NaCl, 0.1 M potassium phosphate buffer (pH 7.4), 10 mM NaN 3 , 7 mM deoxyribose, 5 mM ferrous ammonium sulfate and distilled water The mixture was added so as to mix well in the vortex and allowed to stand at 37 ° C for 15 minutes. 67 μl of serum was taken and mixed with 75 μl of 8.1% sodium dodecyl sulfate, 500 μl of 20% acetic acid and 25 μl of distilled water. 333 μl of 1.2% thiobarbituric acid was added thereto, followed by heating in a water bath (100 ° C.) for 30 minutes, cooling at room temperature, and centrifugation at 700 × g for 5 minutes to measure absorbance at a wavelength of 532 nm. The content of hydroxyl radical (nmole / mg protein) was quantified by the calibration curve.

1-14. Blood Superoxide dismutase ( SOD ) Active measurement

It was quantified according to the method of Mirsa and Fridovich (Mirsa, HP and Fridovich, I., 1972). Serum was added to a certain amount of reaction solution [1 mmol / L adrenalin (pH 2), 50 mmol / L glycin (pH 10.2)] and reacted for 3 minutes at 30 o C and the amount of adrenochrome produced at 480 nm was measured. Enzyme activity was expressed as U / g protein of superoxide dismutase. One unit of SOD was calculated as 50% inhibition of adrenochrome production.

2. Experimental results

2-1. Poloxamer -407 Treatment of Hyperlipidemia Model Serum Lipids  For effect

Hyperlipidemia (Illingworth, DR Harris, W. S and Connor, W. E, 1984) is known to have higher serum lipid concentrations than normal, and the exact cause of this symptom is high blood glucose or metabolic abnormalities in Increased or caused by tissue damage due to lipids and oxidation (Kim Song-Jeon, Man-Su Kim, 1991; Baek Kyung et al., 1993)

Preliminary experiments were carried out to investigate the suppression of hyperlipidemia according to the treatment of coarse powder and cod roe powder. Each fraction was administered orally for 4 weeks at each dose (100, 200 mg / kg) and poloxamer-407 was administered on the test day. Triglyceride and cholesterol contents were observed.

Poloxamer-407, a substance known to cause hypertriglyceridemia by enhancing HMG-CoA reductase activity in the liver and strongly inhibiting lipoprotein lipase, an enzyme involved in the hydrolysis of circulating blood triglycerides on the surface of epithelial cells. , 1994) was injected 48 hours after injection of 300mg / kg (30%, 1 ml ip) and blood triglycerides were measured. As a result, the amount of triglycerides significantly increased with the administration of poloxamer-407 compared to the normal group. In the 200mg / kg administration group, the total cholesterol content decreased to 3% and 13%, respectively, in 200mg / kg administration of cod and cod roe powder (see Table 2).

Figure 112010041851958-pat00004

2-2. Triton WR Treatment of Hyperlipidemia Model Serum Lipids  For effect

Preliminary experiments were carried out to investigate the suppression of hyperlipidemia according to the treatment of cod roe powder and cod roe powder. Each fraction was administered orally for 4 weeks by dose (100, 200 mg / kg), and triton WR-1339 (TWR) The amount of triglyceride and cholesterol in the blood was observed.

There was no significant difference in triglycerides, but the amount of cholesterol was significantly decreased at 200 mg in cod and cod roe (see Table 3).

Figure 112010041851958-pat00005

2-3. Weight change

Dietary hyperlipidemia was induced by an overdose of high fat diet for 6 weeks, and coarse powder and cod roe powder were orally administered for 4 weeks, and weight change was measured every week. The rats fed a high fat diet weighed 331.4 ± 2.8 at 6 weeks, which was about 14.5% higher than the rats fed a normal diet (6 weeks: 283.6 ± 1.7). In the hyperlipidemic rats, the coarse powder sample and coarse roe powder sample were found to show weight loss effect, and the colied roe powder sample showed the best weight loss effect. In particular, rats fed 200mg / kg of cod roe powder weighed 296.5 ± 1.4g at 6 weeks, with a 10.6% weight loss (see Table 4).

Figure 112010041851958-pat00006

2-4. Weight fluctuations of adipose tissue

Table 5 shows the effects of coarse powder and cod roe powder on adipose tissue in rats induced dietary hyperlipidemia.

After 4 weeks of coarse powder and coarse roe powder, the adipose tissue showed a lower tendency to increase in the experimental group treated with coarse powder and coarse roe powder than the control group, and increased statistically significantly at 200 mg administration rather than 100 mg. Confirmed.

As a result, it was confirmed that the 200 mg treated group of cod roe sample had the most anti-obesity effect (see Table 5).

Figure 112010041851958-pat00007

2-5. Changes in Serum Lipid Components

After oral administration of each sample in hyperlipidemia-induced rats, the results of serum lipid concentration changes are shown in Table 6.

In this experiment, there was no significant difference between total lipid and triglyceride, but phospholipid decreased by 3% and 4% when 200mg / kg of coarse powder and cod roe powder, respectively, compared to the control group (see Table 6). .

Figure 112010041851958-pat00008

2-6. serum cholesterol  Content change and arteriosclerosis index

Table 7 shows the effects of dietary hyperlipidemia on the changes in serum cholesterol content and arterial stiffness index between rats fed coarse powder and cod roe powder.

As can be seen from Table 7, the total cholesterol level of the diet-induced hyperlipidemia in the rat was 139.7 ± 10.3 mg / dL, but 200mg oral and 120.3 ± 4.27 mg / dL and 103.9 ± 3.26 mg / dL 14.0% and 26% respectively.

On the other hand, HDL-cholesterol showed no significant difference, but LDL-cholesterol induced dietary hyperlipidemia was 87.3 ± 7.13 mg / dL, but after oral administration of coarse powder and cod roe powder at 200 mg, the results were 67.1 ±. It was found that the decrease was 5.19 and 50.8 ± 5.11. This can be said to prove that cod roe and cod roe have an effect on lowering LDL-Cholesterol in the blood. Atherosclerotic index was 2.86 ± 0.81 in rats inducing dietary hyperlipidemia, and the rats fed 200 mg of coarse powder and cod roe powder were 2.21 ± 0.45 and 1.71 ± 0.41, respectively, which were significantly lowered to 23% and 40%, respectively. This suggests that cod roe and cod roe are effective in lowering the arteriosclerosis index. Hyperlipidemia is due to increased synthesis of triglycerides in the small intestine, increased synthesis of triglycerides in the liver, decreased synthesis of HDL-cholesterol, increased synthesis and secretion of VDL-cholesterol (Eddy, NB, 1953; D , Amour, FE , Smith, DL, 1994; Imad Damaj, M. Martin, BR, 1996). In this experiment, the reduction of blood LDL-cholesterol and the reduction of atherosclerosis were shown to be effective for hyperlipidemia (see Table 7).

Figure 112010041851958-pat00009

2-7. Hepatic tissue and Feces  Triglycerides and cholesterol  Content change

Table 8 shows the effects of oral administration of coarse powder and cod roe powder on dietary hyperlipidemia-induced changes in lipid and cholesterol contents in liver tissues.

In rats fed orally administered coarse powder and coarse roe powder, dietary hyperlipidemia was induced to decrease the content of neutral lipid in coarse powder and coarse roe powder, and decreased to 10% and 31%, respectively.

This suggests that the administration of cod roe powder and cod roe powder affect the lipid metabolism of liver tissue, which may be indirectly proved to be effective in diseases such as hyperlipidemia. Cholesterol content was also decreased in coarse powder and cod roe powder and decreased by 10% and 17% when 200 mg was administered (see Table 8).

Compared with the control group, lipid content in the feces of rats fed dietary hyperlipidemia and oral administration of coarse powder and cod roe powder was significantly 9% and 10% in 200 mg colied powder. Decreases (see Table 9).

This is because the greater the effect of delaying the absorption of bile acids, the greater the effect of lowering cholesterol (Winter, CA, Risley, EA and Nuss, GW, 1963; Winter, CA, 1982). I thought it might increase the role of eliminating cholesterol. In addition, measuring bile acid concentrations may help to obtain good data.

Figure 112010041851958-pat00010

Figure 112010041851958-pat00011

2-8. Changes in Lipid Peroxide Production in Blood

Table 10 shows the effects of dietary hyperlipidemia on the lipid lipid peroxidation and free radicals after oral administration of coarse powder and cod roe powder samples. In the case of blood lipid peroxide, the hyperlipidemia-induced diet group and the normal diet group were 47.7 ± 2.43 nmole / mL in the hyperlipidemia-induced diet group, 1.8 times more than the normal diet group, 25.9 ± 1.76 nmole / mL.

In this experiment, the amount of lipid peroxidation and free radicals decreased to 10% and 16%, respectively, in the experimental group containing 200mg / kg of cod roe powder and cod roe powder.

Blood lipid peroxidation is known to cause cytotoxicity and cause aging and pathology of various diseases and is detoxified by the action of detoxification mechanisms (Rhee, SK, Cheon, SS, Kim, DS, 2001; , Kim Eun-hee, Park Se-young, Choi Jee-hye, 2000; Oh, SH, Kim, DJ, 1995).

As a result of oral administration of cod roe and cod roe, the amount of lipid peroxidation and free radicals was decreased (see Table 10).

Figure 112010041851958-pat00012

2-9. Blood hydroxyl radical  Generated and superoxide dismutase ( SOD ) activation

Table 11 shows the effects of dietary hyperlipidemia on the lipid lipid peroxidation and free radicals after oral administration of coarse powder and cod roe powder samples.

Blood hydroxy radicals were 1.9 times higher in the hyperlipidemic diet group than in the normal diet group. There was no significant difference in the amount of free radicals from the experimental group of coarse powder and cod roe powder, but the amount of free radicals in all experimental groups was reduced. This suggests that cod roe and cod roe are effective for the prevention of hyperlipidemia (see Table 11).

Figure 112010041851958-pat00013

Hereinafter, the formulation examples of the composition of the present invention will be described, but the present invention is not intended to limit the present invention but merely to explain in detail.

Formulation example  One. Sanje  Produce

Cod roe (MR-D) 20 mg

Lactose 100 mg

Talc 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

Formulation example  2. Preparation of tablets

Cod roe (MR-D) 10 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

Formulation example  3. Preparation of capsules

Cod roe (MR-D) 10 mg

3 mg of crystalline cellulose

Lactose 14.8 mg

Magnesium Stearate 0.2 mg

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

Formulation example  4. Preparation of injections

Egg (MR) 10 mL

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Na2HPO4,12H2O 26 mg

(2 ml) per 1 ampoule according to the usual injection preparation method.

Formulation example  5. Liquid  Produce

Egg (MR) 20 mL

10 g of isomerized sugar

5 g of mannitol

Purified water

Each component was added to purified water in accordance with the usual liquid preparation method and dissolved, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was adjusted to 100 ml with purified water, And sterilized to prepare a liquid preparation.

Formulation example  6. Manufacture of health food

Cod roe (MR-D) 1000 mL

Vitamin mixture quantity

70 [mu] g of vitamin A acetate

Vitamin E 1.0 mg

0.13 mg vitamin B1

0.15 mg of vitamin B2

0.5 mg vitamin B6

0.2 [mu] g vitamin B12

10 mg vitamin C

Biotin 10 μg

Nicotinic acid amide 1.7 mg

50 ㎍ of folic acid

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

15 mg of potassium phosphate monobasic

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

100 mg of calcium carbonate

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

Formulation example  7. Manufacture of health drinks

Cod 1000 ml

Citric acid 1000 mg

100 g of oligosaccharide

Plum concentrate 2 g

Taurine 1 g

Purified water was added to a total of 900 ml

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, &Lt; / RTI &gt;

Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.

Claims (6)

  1. A first step of collecting and washing the pollack of pollack and immersing it in a seasoning solution for 1 to 60 hours during the screening and selection process; A second step of preparing fermented cod roe by adding red pepper powder, sugar, garlic, syrup, etc. to the seasoned cod roe for 1 hour to 60 hours at 0 ° C. to 50 ° C .; Pharmaceutical composition for the prevention and treatment of obesity or hyperlipidemia, which comprises the cod roe obtained in the third step of manufacturing the freeze-dried cod roe powder as an active ingredient.
  2. delete
  3. delete
  4. delete
  5. A first step of collecting and washing the pollack of pollack and immersing it in a seasoning solution for 1 to 60 hours during the screening and selection process; A second step of preparing fermented cod roe by adding red pepper powder, sugar, garlic, syrup, etc. to the seasoned cod roe for 1 hour to 60 hours at 0 ° C. to 50 ° C .; Health functional foods for the prevention and improvement of obesity or hyperlipidemia, comprising as an active ingredient obtained by the manufacturing process of the third step to freeze-dried dried powdered cod roe.
  6. delete
KR1020100061802A 2010-06-29 2010-06-29 Composition comprising the salted Alaska pollack roe or Alaska pollack roe for preventing and treating obesity or hyperlipidemia and atherosclerotic-vascular diseases KR101189865B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020100061802A KR101189865B1 (en) 2010-06-29 2010-06-29 Composition comprising the salted Alaska pollack roe or Alaska pollack roe for preventing and treating obesity or hyperlipidemia and atherosclerotic-vascular diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020100061802A KR101189865B1 (en) 2010-06-29 2010-06-29 Composition comprising the salted Alaska pollack roe or Alaska pollack roe for preventing and treating obesity or hyperlipidemia and atherosclerotic-vascular diseases

Publications (2)

Publication Number Publication Date
KR20120001150A KR20120001150A (en) 2012-01-04
KR101189865B1 true KR101189865B1 (en) 2012-10-10

Family

ID=45608884

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020100061802A KR101189865B1 (en) 2010-06-29 2010-06-29 Composition comprising the salted Alaska pollack roe or Alaska pollack roe for preventing and treating obesity or hyperlipidemia and atherosclerotic-vascular diseases

Country Status (1)

Country Link
KR (1) KR101189865B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101425899B1 (en) * 2012-12-03 2014-08-05 한국식품연구원 Seasoned-dried food using fish roe and manufacturing method thereof
CN103445164B (en) * 2013-09-04 2015-12-23 三峡大学 A kind of content fish egg food and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080089999A1 (en) 2006-10-17 2008-04-17 David Alpern Method for producing a nutritional supplement using fish roe

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080089999A1 (en) 2006-10-17 2008-04-17 David Alpern Method for producing a nutritional supplement using fish roe

Also Published As

Publication number Publication date
KR20120001150A (en) 2012-01-04

Similar Documents

Publication Publication Date Title
JP5295925B2 (en) Lipid metabolism improving composition and food
EP1311258B1 (en) Compositions containing hypotriglyceridemically active stilbenoids
RU2234928C2 (en) Products of sea cucumber carotinoid-lipid, protein-containing fractions and methods for their application
KR20080015495A (en) Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
KR19990036207A (en) Lipid metabolism improvers
CA2520207C (en) Composition comprising bamboo extract and the compounds isolated therefrom showing treating and preventing activity for inflammatory and blood circulation disease
US8933217B2 (en) Compounds, compositions, and methods for protecting brain health in neurodegenerative disorders
JP5189365B2 (en) Body lipid improving composition
TWI255181B (en) Remedies for enhancing of the production of nerve growth factor
JP2004519455A (en) Regulation of lipid and / or bone density and compositions therefor
JPH0741421A (en) Preventive agent or improver for medical symptom using leukotriene b4 (ltb4)
US20100239603A1 (en) Combinations of Botanical Extracts for Promoting Cardiovascular Health
JP2008526737A (en) Compositions containing gramineous plant extracts and their use for the prevention and treatment of ischemic and degenerative brain diseases
AU2004238122B2 (en) Composition for lowering lipid in body
CN101632655B (en) Anti-aging resveratrol and bioflavonoids nutritional composition
JP2002524505A (en) For the prevention or treatment of diseases due to high blood lipid levels, a composition comprising cinnamic acid derivative
US10076553B2 (en) Dietary product intended for the prevention of cardiometabolic risk
ES2719098T3 (en) Compositions comprising a lofenol
KR100573423B1 (en) Sea cucumber carotenoid lipid fraction products and methods of use
ES2431142T3 (en) Fat accumulation inhibitor for the treatment of metabolic syndrome
JP2006001929A (en) Glucose uptake-activating agent in muscular cell, glut4 translocation-activating agent in muscular cell, glut4 translocation inhibitory agent in fat cell, preventing agent of diabetic complication and beverage and foodstuff containing them
TW518221B (en) Antiallergic agent and antiallergic foods or drinks comprising 4,5-dihydroxy-2-cyclopenten-1-one or its optical activators or their salts
JP5443979B2 (en) Novel leukotriene receptor antagonist
EP1618875B1 (en) Composition for inhibition or prevention of bone density lowering
Xu et al. A study of the comparative effects of hawthorn fruit compound and simvastatin on lowering blood lipid levels

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20151001

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee